Lipanthylnano (Fenofibrate (Nanonised))

Lipanthylnano (fenofibrate) is used to modify lipid metabolism in several dyslipidaemic conditions.

• Hypertriglyceridemia: reduces serum triglyceride concentrations and lowers risk of pancreatitis.
• Mixed dyslipidemia: decreases triglycerides while modestly raising HDL‑cholesterol.
• Primary hypercholesterolemia (adjunct therapy): complements statin treatment to improve overall lipid profile.

• Fenofibrate activates peroxisome proliferator‑activated receptor‑alpha (PPARα), a nuclear transcription factor that regulates genes involved in fatty‑acid oxidation, lipoprotein metabolism and inflammation. Activation enhances lipolysis, increases clearance of triglyceride‑rich lipoproteins, and raises high‑density lipoprotein synthesis, resulting in lowered plasma triglycerides and modest improvements in LDL‑cholesterol and HDL‑cholesterol levels.

Fenofibrate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
• Elevated liver enzymes: transient rise in ALT or AST.
• Muscle pain: mild myalgia without weakness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown that can lead to renal failure.
• Hepatotoxicity: significant liver injury or jaundice.
• Gallstone formation: precipitation of cholesterol stones.

Before initiating therapy, several safety considerations should be addressed.

• Liver function monitoring: assess ALT/AST before treatment and periodically during therapy.
• Renal function assessment: evaluate creatinine clearance, especially in patients with renal impairment.
• Gallbladder disease evaluation: avoid use in patients with active gallstone disease.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; safety data are limited.
• Drug interactions: review concomitant medications for potential interactions, especially with statins or anticoagulants.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Fenofibrate can interact with several medicines, requiring caution.

Major Interactions (Avoid)

• Gemfibrozil: combined use markedly increases risk of myopathy and rhabdomyolysis.
• Cyclosporine: may raise fenofibrate plasma concentrations, enhancing toxicity.
• Warfarin: fenofibrate can potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely)

• Statins (e.g., simvastatin, atorvastatin): increased risk of muscle toxicity; dose adjustment may be needed.
• Bile acid sequestrants (e.g., cholestyramine): may reduce fenofibrate absorption, lowering efficacy.
• Oral contraceptives: may slightly increase triglyceride levels; monitor lipid profile.